Pfizer, J&J Alzheimer's drug falls short in study

SAN FRANCISCO (MarketWatch) 

Pfizer Inc.  PFE -0.42% said late Monday that an experimental Alzheimer's treatment it's working on with Johnson & Johnson Inc.  unit Janssen Pharmaceuticals did not meet clinical endpoints in a late-stage study

In the study, a certain class of patients with mild-to-moderate Alzheimer's disease given an intravenous form of the drug bapineuzumab did not fare any better in cognitive and functional performance compared with those given a placebo, Pfizer said

The Phase III drug study is one of four that Pfizer is partnering on with the J&J unit

The three other studies of the drug will continue as planned, Pfizer said